OTC Markets OTCPK USD

Imugene Limited (IUGNF)

0.0200

0.0000

(0.00%)

At close: April 23 at 4:00:00 PM EDT

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent DirectorsWELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. “We are delighted to welcome Kim and Bo to our Boar

GlobeNewswire 22 days ago

VERV

IUGNF
0.00%
ABOS
ASX Penny Stocks To Watch In March 2025

The Australian stock market recently saw the ASX200 close down by 0.4% at 7,828 points, with Health Care and Telecommunication sectors showing resilience while Utilities and Real Estate lagged behind. In this context, penny stocks—often seen as a niche investment area—still hold potential for investors seeking growth opportunities in smaller or newer companies. Despite their somewhat outdated label, these stocks can offer significant returns when backed by strong financial health; we'll...

Simply Wall St. last month

SBMJF

IUGNF
0.00%
JDO.AX
February 2025's ASX Penny Stocks With Growth Potential

The Australian stock market has faced a slight downturn, with the ASX200 down 0.36% amid concerns over new tariffs on aluminium and steel imposed by the Trump administration. Despite these challenges, certain sectors like Utilities and Health Care have shown resilience, highlighting opportunities for investors to explore undervalued segments of the market. Penny stocks, often representing smaller or newer companies, remain a relevant investment area; when backed by strong financials and...

Simply Wall St. 2 months ago

RDBBF

IUGNF
0.00%
OMHLF
ASX Penny Stocks To Watch In January 2025

As 2024 closed, the Australian market experienced a downturn, with the ASX finishing on a two-day decline, highlighting profit-taking across most sectors. Despite this broader market pullback, investors continue to seek opportunities in undervalued areas such as penny stocks. Though often considered niche or outdated, these smaller or newer companies can offer significant growth potential when supported by strong financials.

Simply Wall St. 3 months ago

TPGTF

LRSRF

IUGNF
0.00%
ASX Penny Stocks To Watch In November 2024

The Australian market has recently seen the ASX200 reach new heights, closing up 0.45% at 8,444 points, with Health Care and Financials leading the charge despite mixed performances in other sectors. In such a dynamic market landscape, identifying promising investment opportunities requires careful consideration of financial health and growth potential. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing possibilities for investors seeking value beyond...

Simply Wall St. 4 months ago

AX1.AX

VNT.AX

IUGNF
0.00%
3 Promising ASX Penny Stocks With Market Caps Over A$10M

The Australian market remained flat over the last week, but it has seen a 22% rise in the past 12 months, with earnings forecasted to grow by 12% annually. For investors willing to explore beyond established names, penny stocks—often smaller or newer companies—can offer intriguing opportunities. While the term might seem outdated, these stocks can still provide significant growth potential when supported by strong financials and solid fundamentals.

Simply Wall St. 5 months ago

RIL.AX

CTLLF

IUGNF
0.00%
Those who invested in Imugene (ASX:IMU) five years ago are up 144%

It might be of some concern to shareholders to see the Imugene Limited ( ASX:IMU ) share price down 19% in the last...

Simply Wall St. 6 months ago

IUGNF
0.00%
Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)

10 patients have been treated to date with azer-cel in the Phase 1b diffuse large B-cell lymphoma (DLBCL) trial Cohort A: 6 patients were treated with azer-cel and lymphodepletion (chemotherapy)1Cohort B: 4 patients were treated with azer-cel, lymphodepletion (chemotherapy)1, and interleukin 2 (IL-2) 3 complete responses - The first 2 patients treated in Cohort B achieved a complete response (CR) and 1 patient treated in Cohort A achieved a CRDurability of CRs in Cohort B; >120 days and >90 days

GlobeNewswire 7 months ago

IUGNF
0.00%
Breakeven On The Horizon For Imugene Limited (ASX:IMU)

Imugene Limited ( ASX:IMU ) is possibly approaching a major achievement in its business, so we would like to shine some...

Simply Wall St. 8 months ago

IUGNF
0.00%
Is Imugene (ASX:IMU) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 10 months ago

IUGNF
0.00%
Those who invested in Imugene (ASX:IMU) five years ago are up 361%

For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly...

Simply Wall St. 11 months ago

IUGNF
0.00%

Performance Overview

Return	IUGNF	S&P/ASX 200 [XJO] (^AXJO)
YTD	-6.98%	-2.34%
1-Year	-61.90%	+3.71%
3-Year	-86.67%	+6.62%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Imugene Limited (IUGNF)

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

ASX Penny Stocks To Watch In March 2025

February 2025's ASX Penny Stocks With Growth Potential

ASX Penny Stocks To Watch In January 2025

ASX Penny Stocks To Watch In November 2024

3 Promising ASX Penny Stocks With Market Caps Over A$10M

Those who invested in Imugene (ASX:IMU) five years ago are up 144%

Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)

Breakeven On The Horizon For Imugene Limited (ASX:IMU)

Is Imugene (ASX:IMU) In A Good Position To Deliver On Growth Plans?

Those who invested in Imugene (ASX:IMU) five years ago are up 361%

Performance Overview